和仁科技(300550) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥107,222,436.58, representing a year-on-year growth of 25.17%[8] - Net profit attributable to shareholders of the listed company was ¥13,441,931.58, up 16.78% year-on-year[8] - Basic earnings per share increased by 20.00% to ¥0.12[8] - The company reported a net profit excluding non-recurring gains and losses of ¥9,533,562.74, down 6.75% year-on-year[8] - Total operating revenue for the current period reached ¥107,222,436.58, a significant increase of 25.2% compared to ¥85,661,237.43 in the previous period[43] - Net profit for the current period was ¥14,918,062.34, representing a 60.5% increase from ¥9,305,739.16 in the previous period[44] - Basic and diluted earnings per share increased to ¥0.12 from ¥0.10, reflecting a 20% growth[45] - Operating profit for the current period was ¥13,293,746.22, a rise of 10.4% compared to ¥12,043,731.26 in the last period[44] - Net profit for the period was ¥34,248,576.00, representing a 55.5% increase from ¥22,014,760.20 in the same period last year[52] - Basic earnings per share increased to ¥0.31 from ¥0.23, reflecting a growth of 34.8%[53] - Total comprehensive income for the period was ¥34,248,576.00, compared to ¥22,014,760.20 in the same period last year, marking a 55.5% increase[53] Assets and Liabilities - Total assets at the end of the reporting period reached ¥945,780,035.95, an increase of 0.21% compared to the end of the previous year[8] - The company's equity increased to CNY 620,066,776.77 from CNY 558,019,239.79, representing a growth of approximately 11.1%[41] - Current liabilities totaled CNY 337,345,969.10, down from CNY 373,119,476.25, indicating a decrease of about 9.6%[40] - The total liabilities decreased to CNY 339,103,699.03 from CNY 374,877,206.18, reflecting a decrease of approximately 9.6%[40] - The company’s retained earnings increased to CNY 244,970,560.47 from CNY 212,592,110.99, showing a growth of about 15.2%[41] - The company’s total current assets rose to CNY 717,531,300.26 from CNY 697,985,827.89, indicating an increase of about 2.4%[39] Cash Flow - Cash flow from operating activities showed a net outflow of ¥47,431,593.23, a decrease of 25.56% year-to-date[8] - The company’s total cash flow from operating activities was ¥275,265,669.33, compared to ¥160,806,552.43 in the previous period[59] - The net cash flow from operating activities was negative at CNY -47,431,593.23, an improvement compared to CNY -63,716,530.64 in the same period last year[60] - Total operating cash outflow reached CNY 361,080,649.95, an increase from CNY 256,841,962.54 in the previous year, reflecting a rise of about 40.5%[60] Shareholder Information - The total number of shareholders at the end of the reporting period was 10,973[12] - The largest shareholder, Hangzhou Panyuan Investment Co., Ltd., held 53.74% of the shares, amounting to 63,042,000 shares[12] - The total number of restricted shares at the beginning of the period was 75,267,500, with no new shares added during the period[19] - The number of restricted shares held by Hangzhou Panyuan Investment Co., Ltd. was 63,042,000, which will be released on October 18, 2019[15] - The company has a structured plan for the release of restricted shares, as detailed in the 2017 Restricted Stock Incentive Plan[18] Investments and Expenses - Long-term equity investments reached ¥2,355,800.32, marking a 100% increase from previous periods due to investment in Zhongyuan Heren Medical Technology Co., Ltd.[22] - Research and development expenses were ¥9,873,531.27, slightly up from ¥9,106,030.82, indicating continued investment in innovation[43] - Management expenses rose by 57.88% to ¥46,056,465.63, mainly due to increased equity incentive costs[22] - The company reported an investment income of ¥2,561,062.54, an increase from ¥1,472,352.76 in the previous period[43] - The company incurred a credit impairment loss of ¥11,420,869.96, with no comparable figure from the previous period[52]